The aim of the study is to evaluate safety of short hydration with cisplatin administration. The main outcome is renal dysfunction following cisplatin use with short hydration protocol. Another group of patients received conventional hydration is the historical control for comparison (Randomized phase II design with a reference standard treatment control arm)

Inclusion Criteria:

• Cancer patient who has plan to receive first cycle of cisplatin >= 60 mg/m2
• Normal serum creatinine and creatinine clearance >= 50 ml/min
• Age < 75 years old
• Serum albumin >= 3 g/dl
• Plan to receive optimal antiemetic regimen consisting of olanzapine or neurokinase 1 receptor antagonist

Exclusion Criteria:

• The patient who receives other chemotherapy with adminstration volume higher than 500 ml
• Prior heart failure or known left ventricular ejection fraction > 50%
• Prior renal dysfunction within 3 months
• Uncontrolled renal disease
• current use of diuretic or non-steroidal anti-inflammatory drug (NSAIDs) or starting angiotensin converting enzyme inhibitor (ACEI) or angiotensin receptor blockade (ARB) within 3 months